MedTrace Logo

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis

NCT00757848 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-08-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate if treatment with AZD9668 for 28 days is effective in treating Cystic Fibrosis (CF) and if so how it compares to placebo (a substance which does not have any action).

Conditions

Interventions

DRUG

AZD9668

60 mg, oral tablet, twice daily for 28 days

DRUG

AZD9668 Placebo equivalent

Match placebo to 60 mg, oral tablet, twice daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Prof. Elborn · Belfast hospital

  • Joanna Marks-Konczalik · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Denmark
  • Germany
  • Poland
  • Russia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00757848 on ClinicalTrials.gov